Biofrontera Inc (BFRI) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The price trajectory of Biofrontera Inc. (BFRI), which has an EV/EBITDA multiple of 0.00, reflects risks stemming from litigation with creators of similar products and a dependence on a single treatment method. The business relies on clinic loyalty, supplying equipment and gels under strict FDA supervision. Growth is driven by the expansion of the sales force, broader insurance coverage, and sales of Ameluz systems in the US.

This indicator assesses business value by accounting for net debt relative to earnings before interest, taxes, depreciation, and amortization. By analyzing the current EV/EBITDA ratio of Biofrontera Inc. (BFRI), an investor determines the payback period of assets through real cash flow generation. For Biofrontera Inc. (BFRI), this metric confirms the stability of a model where patent protection and FDA certification create a defensive barrier, ensuring steady income to service obligations.